Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Demyelinating Diseases

ClinicalTrials.gov lists 4,041 trials for Demyelinating Diseases or a narrower condition beneath it. Biogen has the most among industry and government lead sponsors, with 165.

MeSH D003711 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 268 Phase 1/2 Phase 1/2 132 Phase 2 Phase 2 400 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 329 Phase 4 Phase 4 233 Not applicable Not applicable 1,378 Observational Observational 1,223 Phase 1 Phase 1 268 Phase 1/2 Phase 1/2 132 Phase 2 Phase 2 400 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 329 Phase 4 Phase 4 233 Not applicable Not applicable 1,378 Observational Observational 1,223

Trials per phase (log scale)

1 more section with rows

100 of the 4,041 trials are tagged with Demyelinating Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Demyelinating Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Demyelinating Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 279

1990: 1 trials (Phase 2 1) 1991: 2 trials (Not applicable 1, Phase 3 1) 1992: 3 trials (Observational 1, Phase 3 2) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Phase 4 1) 1995: 6 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2/3 1, Phase 1 1) 1996: 4 trials (Observational 2, Phase 3 2) 1997: 2 trials (Phase 2 1, Phase 1 1) 1998: 6 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 1999: 13 trials (Observational 3, Phase 4 2, Phase 3 3, Phase 2 4, Phase 1/2 1) 2000: 2 trials (Observational 2) 2001: 18 trials (Not applicable 1, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2002: 27 trials (Observational 3, Phase 4 2, Phase 3 10, Phase 2 9, Phase 1/2 3) 2003: 42 trials (Observational 6, Not applicable 3, Phase 4 8, Phase 3 5, Phase 2 13, Phase 1/2 3, Phase 1 4) 2004: 44 trials (Observational 9, Not applicable 3, Phase 4 10, Phase 3 5, Phase 2/3 5, Phase 2 8, Phase 1/2 2, Phase 1 2) 2005: 58 trials (Observational 13, Not applicable 5, Phase 4 4, Phase 3 15, Phase 2/3 1, Phase 2 16, Phase 1/2 1, Phase 1 3) 2006: 74 trials (Observational 15, Not applicable 11, Phase 4 5, Phase 3 18, Phase 2/3 1, Phase 2 16, Phase 1/2 4, Phase 1 4) 2007: 76 trials (Observational 20, Not applicable 9, Phase 4 4, Phase 3 15, Phase 2/3 3, Phase 2 14, Phase 1/2 3, Phase 1 8) 2008: 89 trials (Observational 30, Not applicable 7, Phase 4 9, Phase 3 16, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 8) 2009: 97 trials (Observational 25, Not applicable 14, Phase 4 7, Phase 3 9, Phase 2/3 4, Phase 2 21, Phase 1/2 6, Phase 1 11) 2010: 124 trials (Observational 33, Not applicable 18, Phase 4 10, Phase 3 15, Phase 2/3 2, Phase 2 21, Phase 1/2 9, Phase 1 16) 2011: 113 trials (Observational 32, Not applicable 26, Phase 4 12, Phase 3 11, Phase 2/3 5, Phase 2 17, Phase 1/2 4, Phase 1 6) 2012: 140 trials (Observational 51, Not applicable 32, Phase 4 13, Phase 3 11, Phase 2/3 3, Phase 2 15, Phase 1/2 7, Phase 1 8) 2013: 153 trials (Observational 35, Not applicable 41, Phase 4 19, Phase 3 15, Phase 2/3 3, Phase 2 17, Phase 1/2 11, Phase 1 12) 2014: 181 trials (Observational 47, Not applicable 63, Phase 4 17, Phase 3 15, Phase 2/3 2, Phase 2 17, Phase 1/2 8, Phase 1 12) 2015: 171 trials (Observational 47, Not applicable 50, Phase 4 17, Phase 3 15, Phase 2/3 4, Phase 2 16, Phase 1/2 7, Phase 1 15) 2016: 158 trials (Observational 45, Not applicable 61, Phase 4 11, Phase 3 11, Phase 2/3 1, Phase 2 15, Phase 1/2 1, Phase 1 13) 2017: 177 trials (Observational 53, Not applicable 73, Phase 4 11, Phase 3 11, Phase 2/3 5, Phase 2 8, Phase 1/2 7, Phase 1 9) 2018: 212 trials (Observational 61, Not applicable 101, Phase 4 5, Phase 3 14, Phase 2 15, Phase 1/2 5, Phase 1 11) 2019: 236 trials (Observational 77, Not applicable 96, Phase 4 8, Phase 3 18, Phase 2/3 2, Phase 2 19, Phase 1/2 4, Phase 1 12) 2020: 221 trials (Observational 78, Not applicable 90, Phase 4 10, Phase 3 13, Phase 2/3 5, Phase 2 8, Phase 1/2 4, Phase 1 13) 2021: 277 trials (Observational 113, Not applicable 98, Phase 4 11, Phase 3 10, Phase 2/3 4, Phase 2 17, Phase 1/2 6, Phase 1 18) 2022: 237 trials (Observational 81, Not applicable 96, Phase 4 8, Phase 3 16, Phase 2/3 5, Phase 2 16, Phase 1/2 7, Phase 1 8) 2023: 279 trials (Observational 92, Not applicable 143, Phase 4 6, Phase 3 8, Phase 2 15, Phase 1/2 4, Phase 1 11) 2024: 250 trials (Observational 88, Not applicable 107, Phase 4 7, Phase 3 7, Phase 2/3 3, Phase 2 14, Phase 1/2 3, Phase 1 21) 2025: 252 trials (Observational 69, Not applicable 120, Phase 4 5, Phase 3 15, Phase 2/3 1, Phase 2 21, Phase 1/2 5, Phase 1 16)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 248
2025 252
2024 250
2023 279
2022 237
2021 277
2020 221
2019 236
2018 212
2017 177

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 280 trials starting in 2026 and about 260 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 360 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 2,474 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Demyelinating Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 268
Phase 1/2 132
Phase 2 400
Phase 2/3 63
Phase 3 329
Phase 4 233
Not applicable 1,378
Observational 1,223
Expanded access 15

How many Demyelinating Diseases trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 193
Recruiting 463
Enrolling by invitation 57
Active, not recruiting 176
Available 3

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Demyelinating Diseases trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Biogen 165
Novartis Pharmaceuticals 94
Merck KGaA, Darmstadt, Germany 49
Bayer 47
Hoffmann-La Roche 40

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Demyelinating Diseases? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Dimethyl Fumarate 60
METHYLPREDNISOLONE 45
RITUXIMAB 32

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SC interferon beta-1a 81
Ocrelizumab SC 72
fingolimob (FTY) 56
natalizumab SC 50
SC interferon beta-1b 50

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Demyelinating Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Multiple sclerosis relapse 1,787 88
Multiple Sclerosis Relapse 664 29
Urinary tract infection 418 89
Pneumonia 382 106
MULTIPLE SCLEROSIS RELAPSE 282 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Demyelinating Diseases? (172)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Severe Hyponatremia in the Emergency Department Incidence of Cerebral Edema and Risk of Osmotic Demyelination Syndrome. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2026 Yes
Liver X receptors: A therapeutic target in demyelinating disorders. Pharmacological research 2025 Yes
Postural balance and visual dependence in patients with demyelinating neuropathies differ between acquired and hereditary etiologies. Revue neurologique 2025 Yes
Central Dysmyelination in SSADH-Deficient Humans and Mice. Annals of clinical and translational neurology 2025 Yes
Body fluid markers for multiple sclerosis and differential diagnosis from atypical demyelinating disorders. Expert review of molecular diagnostics 2024 Yes

Showing 5 of 172 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages